These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 36717220)

  • 1. Targeting m
    Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
    Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3 Inhibits Antitumor Immunity by Targeting m
    Chen H; Pan Y; Zhou Q; Liang C; Wong CC; Zhou Y; Huang D; Liu W; Zhai J; Gou H; Su H; Zhang X; Xu H; Wang Y; Kang W; Kei Wu WK; Yu J
    Gastroenterology; 2022 Oct; 163(4):891-907. PubMed ID: 35700773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
    Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
    J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.
    Wang S; Gao S; Zeng Y; Zhu L; Mo Y; Wong CC; Bao Y; Su P; Zhai J; Wang L; Soares F; Xu X; Chen H; Hezaveh K; Ci X; He A; McGaha T; O'Brien C; Rottapel R; Kang W; Wu J; Zheng G; Cai Z; Yu J; He HH
    Gastroenterology; 2022 Apr; 162(4):1183-1196. PubMed ID: 34968454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.
    Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J
    Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine deficiency facilitates antitumour immunity by altering m
    Li T; Tan YT; Chen YX; Zheng XJ; Wang W; Liao K; Mo HY; Lin J; Yang W; Piao HL; Xu RH; Ju HQ
    Gut; 2023 Mar; 72(3):501-511. PubMed ID: 35803704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
    Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
    BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA N
    Chen H; Gao S; Liu W; Wong CC; Wu J; Wu J; Liu D; Gou H; Kang W; Zhai J; Li C; Su H; Wang S; Soares F; Han J; He HH; Yu J
    Gastroenterology; 2021 Mar; 160(4):1284-1300.e16. PubMed ID: 33217448
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kang X; Liu C; Ding Y; Ni Y; Ji F; Lau HCH; Jiang L; Sung JJ; Wong SH; Yu J
    Gut; 2023 Nov; 72(11):2112-2122. PubMed ID: 37491158
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Fong W; Li Q; Ji F; Liang W; Lau HCH; Kang X; Liu W; To KK; Zuo Z; Li X; Zhang X; Sung JJ; Yu J
    Gut; 2023 Nov; 72(12):2272-2285. PubMed ID: 37770127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
    Huang TX; Tan XY; Huang HS; Li YT; Liu BL; Liu KS; Chen X; Chen Z; Guan XY; Zou C; Fu L
    Gut; 2022 Feb; 71(2):333-344. PubMed ID: 33692094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.
    Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y
    Front Immunol; 2021; 12():667177. PubMed ID: 34025668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis.
    Chen D; Ji F; Zhou Q; Cheung H; Pan Y; Lau HC; Liang C; Yang Z; Huang P; Wei Q; Cheung AH; Kang W; Chen H; Yu J; Wong CC
    Cancer Res; 2024 Jun; ():. PubMed ID: 38900944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis.
    Yan R; Li J; Xiao Z; Fan X; Liu H; Xu Y; Sun R; Liu J; Yao J; An G; Shi Y; Ge Y
    Cell Mol Gastroenterol Hepatol; 2023; 15(2):463-485. PubMed ID: 36309200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
    Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
    BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
    Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
    Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.